Historical gild News Stories
Gilead’s Q2 Highlights: Long‑Acting Oral HIV PrEP Filing Accepted, EU Expands Trodelvy Label, Phase 3 Lung Cancer Trial Halted
Gilead sees multiple strategic inflection points: FDA accepts supplemental PrEP filing, EU broadens Trodelvy’s use, while a lung‑cancer trial is discontinued.
Gilead’s Bixlenvo Gains FDA Approval: New HIV Tablet and Positive Q2 Beat Spotlight Growth
In the past week, Gilead secured FDA approval for Bixlenvo, a once‑daily HIV tablet, and reported Q2 revenue beat driven by its strong HIV franchise and oncology pipeline.
FDA Approves Bixlenvo: Gilead Unveils Simplified HIV Treatment Option
Gilead Sciences’ newly approved once‑daily single‑tablet Bixlenvo (bictegravir + lenacapavir) streamlines HIV treatment for virologically suppressed adults.
Gilead Sciences' Stock Performance Amid Recent Developments in HIV and Oncology Therapies
Gilead Sciences' stock reflects recent advancements in HIV and oncology treatments.
Gilead Sciences Completes Arcellx Acquisition, Enhancing Multiple Myeloma Treatment Portfolio
Gilead finalizes Arcellx acquisition, bolstering multiple myeloma therapy pipeline.
Gilead Sciences' Stock Declines Amid Arcellx Acquisition and Dividend Increase
Gilead Sciences' stock declines amid Arcellx acquisition and dividend increase.
Gilead Sciences' Stock Declines Amid Industry Shifts and Dividend Increase
Gilead's stock drops 3.13% amid industry debates and dividend hike.
Gilead Sciences' Stock Declines Amid CFO's Share Sale and Market Dynamics
Gilead Sciences' stock dips following CFO's share sale and market factors.
Gilead Stock Enanta, Aicuris Deals Shift Sentiment
This week brought no fresh Gilead disclosures, but sector moves — Enanta advancing RSV and immunology programs and Asahi Kasei’s acquisition of Aicuris (Pritelivir) — could influence investor perception of Gilead’s antiviral, HIV and oncology priorities. The article parses the implications for Gilead (GILD), near-term catalysts, and what investors should watch next.
Gilead's CAR-T Push and Breakthrough HIV Data 2026
Gilead strengthened its growth profile with positive Phase 3 HIV data for a bictegravir–lenacapavir single-tablet regimen and a transformative $7.8B acquisition of Arcellx for CAR‑T oncology assets. Combined with solid 2025 results and a modest dividend raise, these developments create near-term clinical and commercial catalysts for GILD.
Gilead Expands CAR-T, Raises Dividend, Analysts Up
This week Gilead (GILD) advanced its oncology push with the Arcellx acquisition, secured a new FDA label for Yescarta, announced a dividend hike, and drew upgraded analyst price targets—concrete events that strengthen both near-term sentiment and long-term strategy.
Gilead’s $7.8B Arcellx Deal Recasts Oncology Play!
Gilead’s announced $7.8B acquisition of Arcellx this week reshapes its oncology ambitions and has driven near-term stock volatility. This article breaks down the deal, market reaction, competitive HIV pressures from Merck, Gilead’s recent financial footing, and the near-term investor watchlist.
Gilead Q4 Wins, Biktarvy Strength Bolster GILD Now
Gilead's Q4 and full-year 2025 results show resilient HIV and liver franchises, rising oncology contributions, and clear 2026 guidance—offsetting declines in COVID antiviral sales and Medicare headwinds. Recent stock moves reflect market volatility rather than company-specific deterioration.
Gilead Surges: Q4 Beat, Dividend Hike & Upgrades!!
Gilead (GILD) climbed to fresh highs after a February earnings beat, a dividend increase and multiple analyst price-target raises. Strong HIV franchise results—led by Biktarvy and the growing Yeztugo launch—plus durable oncology sales powered the move, while cell-therapy softness and cautious 2026 guidance temper near-term expectations.
Gilead Surges on Trodelvy+Keytruda NEJM Win Shares
Gilead shares climbed to fresh 52-week highs after the New England Journal of Medicine published Phase III ASCENT‑04/KEYNOTE‑D19 results showing strong efficacy for Trodelvy (sacituzumab govitecan) combined with Merck’s Keytruda in PD-L1+ metastatic triple-negative breast cancer. The NEJM publication (Jan 21) and subsequent investor reaction produced consecutive trading-day gains (Feb 4–5, 2026), elevated volume and roughly a 20.8% monthly uptick. This article breaks down the concrete clinical and market catalysts driving GILD’s momentum and the near-term implications for investors.
Gilead Gains: Q4, Analyst Ups, New Antivirals Rise
Gilead (GILD) pushed to fresh 52-week highs late January after a strong quarterly update, analyst upgrades and targeted pipeline additions — notably in HIV, oncology and new HSV antivirals. Recent momentum is driven by robust HIV sales, Trodelvy clinical progress and strategic licensing that broadens Gilead’s antiviral footprint.
Gilead Rally: Lenacapavir, Trodelvy, HSV Deal Now!
Gilead shares climbed to fresh 52-week highs after investor events and concrete pipeline progress. Key catalysts include regulatory momentum for lenacapavir (Yeztugo), promising oncology data for Trodelvy, a strategic HSV licensing deal, and sustained HIV franchise revenue.
Gilead's Yeztugo & HSV Deal Reshape GILD Value Now
Recent analyst upgrades, a strategic HSV licensing deal, and supportive clinical readouts at IDWeek/CROI have boosted Gilead's (GILD) growth narrative — key catalysts for near-term stock movement.
GILD Slides; Licensing Earnings Date Shape Outlook
Gilead shares declined this week as a sector rotation into energy pressured biotech names, while company-specific licensing and collaboration moves modestly bolstered its antiviral pipeline. With shares near $120.67, a forward P/E around 14.5 and a February earnings report ahead, investors must weigh macro headwinds against measured pipeline progress.
Gilead Gains: Lenacapavir, Trodelvy, Veklury Wins!
Gilead’s recent data releases and regulatory moves — new lenacapavir findings at IDWeek, Veklury REDPINE results, Trodelvy+Keytruda efficacy signal, and EU approval for seladelpar — reinforce multi-asset momentum. Strong HIV product sales and targeted oncology wins create clear near-term catalysts for GILD in the Nasdaq‑100.